Digestive and Liver Diseases

Overview

The Digestive & Liver Diseases research area is composed by four groups, whose main goal is the study of the Digestive System diseases. In the Physiology and Pathophysiology of the Digestive Tract group, the gastroenterology line investigates the integrated function of the intestinal tract including secretion, motility and absorption in health and disease. It also studies the interactions of intestinal inflammation with some aspects of enteric flora in inflammatory bowel disease. The liver diseases group deals with viral hepatitis and liver cirrhosis and its complications. And the digestive transplants group studies mostly liver transplantation and the quality of life after it.

This area includes as well the health care research group. The aim of this group is to generate knowledge in the specific area of activity of nurses and collaborate with other health professionals to improve care given to patients.

Publications

115

total

678.821

impact factor

5.868

average impact factor

Director: Rafael Esteban Mur

team

group-zoom

zoom

group-download

download

During 2017, we have continued our internationalization in terms of grants, publications, participation in different consortia, and most importantly our involvement in the design of clinical guidelines for liver diseases in Europe.

66

total

348^.291

impact factor

5^.277

average impact factor

SELECTED ARTICLES

Augustin S, Pons M, Maurice JB, Bureau C, Stefanescu H, Ney M, Blasco H, Procopet B, Tsochatzis E, Westbrook RH, Bosch J, Berzigotti A, Abraldes JG, Genesca J.
Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease.
Hepatology. 2017 Dec;66(6):1980-1988. doi: 10.1002/hep.29363. Epub 2017 Oct 30.
PMID: 28696510
Impact factor: 13,246
Publication type: Paper in international publication
DOI: 10.1002/hep.29363
Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F, Tacke F. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.
PMID: 28427875
Journal:JOURNAL OF HEPATOLOGY
Reference:J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.
Impact factor: 12,486
Publication type: Paper in international publication
DOI: 10.1016/j.jhep.2017.03.021
Rodriguez S, Raurell I, Torres-Arauz M, Garcia-Lezana T, Genesca J, Martell M. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.
Sci Rep. 2017 Jan 13;7:40461. doi: 10.1038/srep40461.
PMID: 28084470
Journal:Scientific Reports
Reference:Sci Rep. 2017 Jan 13;7:40461. doi: 10.1038/srep40461.
Impact factor: 4,259
Publication type: Paper in international publication
DOI: 10.1038/srep40461
Riveiro-Barciela M, Bes M, Rodriguez-Frias F, Tabernero D, Ruiz A, Casillas R, Vidal J, Homs M, Nieto L, Sauleda S, Esteban R, Buti M. Serum Hepatitis B core-related antigen is more accurate than HBsAg to identify inactive carriers, regardless of HBV genotype.
Clin Microbiol Infect. 2017 Mar 11. pii: S1198-743X(17)30152-0. doi: 10.1016/j.cmi.2017.03.003.
PMID: 28288829
Journal:CLINICAL MICROBIOLOGY AND INFECTION
Reference:Clin Microbiol Infect. 2017 Mar 11. pii: S1198-743X(17)30152-0. doi: 10.1016/j.cmi.2017.03.003.
Impact factor: 5,292
Publication type: Paper in international publication
DOI: 10.1016/j.cmi.2017.03.003
Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang HC, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Zeng Z, Chen HL, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10.
PMID: 28802816
Journal:The lancet. Gastroenterology & hepatology
Reference:Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10.
Publication type: Clinical Trials
DOI: 10.1016/S2468-1253(17)30159-0

View all publications